UCB Canada

Name

UCB Canada

Legal name

UCB Canada Inc.

Website

https://ucbcanada.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Biopharmaceutical Medicines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Biopharmaceutical medicines
• Monoclonal antibody therapies
• Immunology treatments
• Neurology medications
• Rare disease therapies

Headquarters

HQ city

Belleville

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations, Others

Revenue model

1. Pharmaceutical product sales: UCB Canada generates revenue through the sale of prescription biopharmaceutical medicines for immunology, neurology, and rare disease conditions. Products are distributed through pharmacy channels and reimbursed via public drug plans, private insurance, Veterans Affairs Canada, and the Non-Insured Health Benefits Program. The company negotiates with the pan-Canadian Pharmaceutical Alliance (pCPA) and provincial formularies for public reimbursement coverage.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

UCB Canada develops, manufactures, and commercializes prescription biopharmaceutical medicines in Canada, focused on immunology (psoriasis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, hidradenitis suppurativa, rheumatoid arthritis), neurology (epilepsy, Parkinson's disease), and rare diseases (generalized myasthenia gravis). The company also operates patient support programs (UCB Cares, UCB Connects, RxHelp ONE, ONWARD) and the FASTRAX Canada diagnostic innovation program for axial spondyloarthritis.

Product overview

UCB Canada is a biopharmaceutical company offering a portfolio of prescription medications primarily focused on immunology, neurology, and rare diseases. The core product portfolio includes BIMZELX® (bimekizumab injection) for psoriasis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and hidradenitis suppurativa; CIMZIA® (certolizumab pegol) for rheumatoid arthritis; BRIVLERA® (brivaracetam), KEPPRA® (levetiracetam), VIMPAT® (lacosamide), and NEUPRO® (rotigotine) for epilepsy and neurological conditions; and RYSTIGGO® (rozanolixizumab) and ZILBRYSQ® (zilucoplan) for generalized myasthenia gravis. Complementing the medication portfolio are patient support programs including UCB Cares™ for CIMZIA® and BIMZELX® patients, UCB Connects for BRIVLERA® and NEUPRO® patients, RxHelp ONE for BRIVLERA® and VIMPAT® patients, and ONWARD™ for rare disease patients. The FASTRAX Canada program provides diagnostic support for axial spondyloarthritis.

Differentiator

Problem solved

Functional benefit

Brands

• UCBCares®: Patient support programs for patients prescribed UCB medicines, covering immunology and neurology conditions.
• FASTRAX

Products and services

• BIMZELX (bimekizumab injection) Monoclonal antibody IL-17A and IL-17F inhibitor approved in Canada for moderate to severe plaque psoriasis, active psoriatic arthritis, active ankylosing spondylitis, active non-radiographic axial spondyloarthritis, and moderate to severe hidradenitis suppurativa. Prescribed by dermatologists and rheumatologists.
• CIMZIA (certolizumab pegol) Tumor necrosis factor (TNF) inhibitor injection indicated for rheumatoid arthritis and other inflammatory conditions.
• BRIVLERA (brivaracetam)
• KEPPRA (levetiracetam)
• VIMPAT (lacosamide)
• NEUPRO (rotigotine transdermal patch)
• RYSTIGGO (rozanolixizumab injection)
• ZILBRYSQ (zilucoplan injection)
• FASTRAX Canada
• UCB Cares Patient Support Program
• UCB Connects
• RxHelp ONE
• ONWARD Patient Support Program
• UCBeyond Scholarship Program

Quantifiable outcome

• BIMZELX (bimekizumab) demonstrated statistically significant HiSCR50 response at Week 16 vs. placebo in BE HEARD I and II Phase III trials enrolling 1,014 patients globally.
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

16 partnerships are on record, tiered core and minor.

• Canada's Drug Agency (CDA-AMC)coreChannel Partner/ Reseller/ Distributor · 9 June 2026CDA-AMC issued a positive reimbursement recommendation with conditions for BIMZELX (bimekizumab) for the treatment of adults with moderate to severe hidradenitis suppurativa. This recommendation reflects clinical evidence submitted, patient and clinician input, and significant unmet need.
• Groupe de recherche en rhumatologie et maladies osseuses (GRMO) — Quebec City cliniccoreStrategic or Co-development Partner · 21 May 2026UCB Canada expanded its FASTRAX Canada program to Quebec City in partnership with GRMO (Groupe de recherche en rhumatologie et maladies osseuses). This site contributes to national perspectives from diverse referral contexts and strengthens the Canadian clinical database supporting early identification and diagnosis of inflammatory back pain. The program involves rheumatologists and Advanced Clinician Practitioners in Arthritis Care (ACPAC) to accelerate axSpA diagnosis in Eastern Canada.
• INESSS (Quebec's health technology assessment body)coreChannel Partner/ Reseller/ Distributor · 26 March 2026INESSS issued a positive reimbursement recommendation for PrBIMZELX (bimekizumab injection) for adults with moderate to severe hidradenitis suppurativa who have inadequate response to conventional systemic therapy. This is the fifth indication for BIMZELX in Canada and is conditional on economic requirements being met.
• Thunder Bay Rheumatology CliniccoreStrategic or Co-development Partner · 21 October 2025UCB expanded its FASTRAX Canada program by opening a site at the Thunder Bay Rheumatology Clinic to improve diagnosis and care for axSpA patients in Northwestern Ontario. This expansion aims to address healthcare disparities, increase access to specialized care, and reduce diagnosis delays for an estimated 855,000 residents, including Indigenous populations.
• pan-Canadian Pharmaceutical Alliance (pCPA)coreChannel Partner/ Reseller/ Distributor · 9 September 2025The pCPA successfully concluded negotiations for PrZILBRYSQ (zilucoplan) and PrRYSTIGGO (rozanolixizumab), marking a necessary step for securing provincial public reimbursement and increased access for Canadians living with generalized myasthenia gravis (gMG).
• Université de Toronto / Dr. Hans KatzbergminorStrategic or Co-development Partner · 9 September 2025Dr. Hans Katzberg, Professor of Medicine at the University of Toronto, has publicly supported public reimbursement of rozanolixizumab and zilucoplan, noting the clinical benefits of subcutaneous therapies for gMG patients.
• University Health Network (UHN) — TorontocoreStrategic or Co-development PartnerUHN Toronto served as the founding site for FASTRAX Canada. The axSpA screening clinic model designed and led by an interprofessional rheumatology team at UHN served as the foundation for FASTRAX expansion across Ontario and beyond. Data from the UHN FASTRAX study showed approximately 22% of patients who completed the FASTRAX pathway received a confirmed axSpA diagnosis.
• L'Hôpital d'Ottawa (TOH)coreStrategic or Co-development PartnerFASTRAX Canada site at L'Hôpital d'Ottawa (TOH) addresses high volumes of specialist referrals in Eastern Ontario and contributes to the provincial strategy for transforming axSpA access and care.
• Advanced Clinician Practitioners in Arthritis Care (ACPAC)coreStrategic or Co-development PartnerACPAC practitioners are highly qualified physiotherapists authorized to perform diagnostic evaluations in accordance with medical directives. They collaborate closely with rheumatologists within the FASTRAX program, using their advanced scope of practice to request MRI exams and blood tests, increasing clinical capacity in rheumatology by accelerating triage and testing.
• Canadian Spondylitis AssociationminorGTM or Marketing PartnerUCB Canada supports the Canadian Spondylitis Association's Lace Up for axSpA campaign during spondylitis awareness month, raising awareness of axSpA challenges and the need for faster diagnosis across Canadian communities.
• Muscular Dystrophy CanadaminorGTM or Marketing PartnerMuscular Dystrophy Canada advocates for people living with gMG and supports increased access to innovative therapies. The organization emphasizes timely access to treatments and encourages provinces to act quickly with listings to ensure patients across Canada can benefit equally.
• Canadian Dermatology Patient Association (ACPD / Alliance canadienne des patients en dermatologie)minorGTM or Marketing PartnerThe ACPD is committed to advocating for the needs of people living with hidradenitis suppurativa and ensuring their voice is heard in decisions that influence access to care. The association emphasizes the need for equitable and timely access to appropriate treatment options.
• Hidradenitis & Me Support GroupminorGTM or Marketing PartnerPatient-founded support group for people living with hidradenitis suppurativa. Founder Latoya Palmer has spoken publicly about the impact of new HS treatments and the importance of patient access to innovative therapies.
• Veterans Affairs CanadacoreChannel Partner/ Reseller/ DistributorFederal government program providing public reimbursement coverage for RYSTIGGO (rozanolixizumab) and ZILBRYSQ (zilucoplan) for eligible Canadian veterans.
• Non-Insured Health Benefits Program (NIHB)coreChannel Partner/ Reseller/ DistributorFederal Indigenous health coverage program providing public reimbursement for RYSTIGGO (rozanolixizumab) and ZILBRYSQ (zilucoplan) for eligible Indigenous beneficiaries in Canada.
• University Health Network (UHN) — Toronto (Provincial multicenter study)coreStrategic or Co-development PartnerA provincial multicenter study led by UHN is generating the clinical evidence needed to validate the systemic benefits of FASTRAX and support its future integration across the health system.

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• AstraZeneca Canada: Canadian arm of AstraZeneca with Saphnelo, Fasenra, and rare disease assets (Alexion). Comparable through Canadian specialty pharma operations spanning immunology and rare disease, including neuromuscular rare disease overlap with UCB's gMG franchise.
• Amgen Canada: Canadian subsidiary of Amgen, marketing biologics across inflammation (Enbrel, Otezla, Tezspire), oncology, and rare disease. Comparable as a biologic-focused multinational pharma with Canadian operations engaging the same rheumatology and dermatology specialists as UCB Canada.
• Novartis Pharmaceuticals Canada: Canadian arm of Novartis selling Cosentyx (IL-17 inhibitor competing with BIMZELX), Kesimpta in neurology, and various specialty medicines. Highly comparable therapeutic overlap in immunology and neurology, and similar go-to-market through pCPA and provincial reimbursement.
• Roche Canada: Canadian subsidiary of Roche with Actemra, Ocrevus, and Hemlibra in neurology and immunology. Comparable therapeutic footprint across neurology and rare disease, including neuromuscular conditions adjacent to gMG.
• Eli Lilly Canada: Canadian arm of Eli Lilly with Taltz (IL-17 inhibitor directly competing with BIMZELX) in psoriasis, PsA, axSpA, plus Olumiant and emerging immunology assets. Highly comparable as a competitor in IL-17 class with Canadian commercial operations.
• Janssen Canada (Johnson & Johnson Innovative Medicine): Canadian pharmaceutical arm of J&J, marketing immunology biologics (Stelara, Tremfya, Remicade) and neurology assets. Directly comparable as a large multinational pharma with a Canadian subsidiary selling specialty biologics into the same rheumatology, dermatology, and gastroenterology channels as UCB Canada.
• Pfizer Canada: Canadian subsidiary of Pfizer with a broad specialty/biologic portfolio including Cibinqo, Xeljanz, and oncology assets. Comparable as a multinational pharma with Canadian operations selling specialty prescription medicines through similar reimbursement and HCP engagement channels.
• AbbVie Canada: Canadian subsidiary of AbbVie, the global leader in immunology with Humira, Skyrizi, and Rinvoq. Direct overlap with UCB Canada's immunology franchise (psoriasis, PsA, axSpA, HS) and competes head-to-head with CIMZIA and BIMZELX in the same specialist channels.
• Sanofi Canada (Sanofi Genzyme): Canadian arm of Sanofi with Dupixent (leading IL-4/13 inhibitor) in immunology/HS, and rare disease assets through Sanofi Genzyme. Direct overlap with UCB's HS franchise and similar patient identification and access programs in Canada.

Direct peers

• argenx Canada: argenx markets Vyvgart (efgartigimod), the first FcRn inhibitor approved for gMG in Canada, and competes head-to-head with UCB's RYSTIGGO in the same anti-FcRn class for AChR antibody-positive gMG patients. Closest direct competitor in the Canadian gMG market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/ucbcanada
• YouTubeyoutube.com/UCB
• Facebookfacebook.com/UCBglobal
• LinkedInlinkedin.com/company/ucbcanada
• Instagraminstagram.com/ucbglobal

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UCB Canada